KLLJ Investments

Long only, deep value, special situations, growth
KLLJ Investments
Long only, deep value, special situations, growth
Contributor since: 2010
Arena: The Belviq Launch And Why The Short Thesis Is Wrong
The Approaching Arena Battle
Assessing Arena's Belviq As A Diabesity Drug
The Vivus Exit Continues
Is Arena The Next Alexion?
A Valuation Model For Arena's Belviq
Is Arena Still A Speculative Stock?
MannKind's Path Forward
Lorcaserin’s Path to Approval
What Analysts Won't Tell You About Arena
Is Lorcaserin the New Miracle Drug?
Is Mannkind the Next Takeover Target?
MannKind Bear Analysts Strike Again
A Giant Leap for MannKind